AR002002A1 - Uso del factor de crecimiento epidermico en la fabricacion de un medicamento en forma de crema hidrofila para el tratamiento del acne. - Google Patents
Uso del factor de crecimiento epidermico en la fabricacion de un medicamento en forma de crema hidrofila para el tratamiento del acne.Info
- Publication number
- AR002002A1 AR002002A1 ARP950100314A AR10031495A AR002002A1 AR 002002 A1 AR002002 A1 AR 002002A1 AR P950100314 A ARP950100314 A AR P950100314A AR 10031495 A AR10031495 A AR 10031495A AR 002002 A1 AR002002 A1 AR 002002A1
- Authority
- AR
- Argentina
- Prior art keywords
- treatment
- acne
- egf
- medicine
- manufacture
- Prior art date
Links
- 208000002874 Acne Vulgaris Diseases 0.000 title abstract 4
- 206010000496 acne Diseases 0.000 title abstract 4
- 238000004519 manufacturing process Methods 0.000 title abstract 3
- 239000008309 hydrophilic cream Substances 0.000 title abstract 2
- 239000003102 growth factor Substances 0.000 title 1
- VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 abstract 4
- 102000009024 Epidermal Growth Factor Human genes 0.000 abstract 3
- 101800003838 Epidermal growth factor Proteins 0.000 abstract 3
- 239000003814 drug Substances 0.000 abstract 3
- 229940116977 epidermal growth factor Drugs 0.000 abstract 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 abstract 2
- 230000001684 chronic effect Effects 0.000 abstract 2
- 229940079593 drug Drugs 0.000 abstract 2
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 abstract 2
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 abstract 2
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 abstract 2
- 239000002562 thickening agent Substances 0.000 abstract 2
- 235000021355 Stearic acid Nutrition 0.000 abstract 1
- 230000000845 anti-microbial effect Effects 0.000 abstract 1
- 239000004599 antimicrobial Substances 0.000 abstract 1
- 239000003995 emulsifying agent Substances 0.000 abstract 1
- 235000011187 glycerol Nutrition 0.000 abstract 1
- 239000003906 humectant Substances 0.000 abstract 1
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 abstract 1
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 abstract 1
- 229960002216 methylparaben Drugs 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 abstract 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 abstract 1
- 230000007170 pathology Effects 0.000 abstract 1
- 239000000902 placebo Substances 0.000 abstract 1
- 229940068196 placebo Drugs 0.000 abstract 1
- 229910000027 potassium carbonate Inorganic materials 0.000 abstract 1
- 239000003755 preservative agent Substances 0.000 abstract 1
- 230000002335 preservative effect Effects 0.000 abstract 1
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 abstract 1
- 239000004405 propyl p-hydroxybenzoate Substances 0.000 abstract 1
- 229960003415 propylparaben Drugs 0.000 abstract 1
- 239000008213 purified water Substances 0.000 abstract 1
- 208000017520 skin disease Diseases 0.000 abstract 1
- 239000002904 solvent Substances 0.000 abstract 1
- 239000008117 stearic acid Substances 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1808—Epidermal growth factor [EGF] urogastrone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/80—Process related aspects concerning the preparation of the cosmetic composition or the storage or application thereof
- A61K2800/86—Products or compounds obtained by genetic engineering
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical & Material Sciences (AREA)
- Zoology (AREA)
- Birds (AREA)
- Dermatology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Abstract
La presente invención está relacionada con la rama de la Medicina y en particular con el empleo del Factor de Crecimiento Epidérmico (EGF) humano yrecombinante en la fabricación de un medicamento para el tratamiento del acné. La composición consiste en una crema hidrófila a base de ácido esteárico comoespesante, carbonato de potasio anhidro como emulsionante y espesante, metilparabeno y propilparabeno como preservativo antimicrobiano, glicerina comohumectante y agua purificada como disolvente y una cantidad de EGF que oscila entre 2 y 50 µg/g, preferiblemente 10 µg/g. Su objetivo técnico es lograr unproducto eficaz para el tratamiento de esta enfermedad crónica de la piel con implicaciones estéticas y psicológicas, demostrándose la utilidad de esteprincipio activo para la fabricación de un medicamento para el tratamiento de dicha patología en un ensayo clínico realizado a doble ciego. De un total de 30pacientes con acné activo tratados diariamente durane 90 días, se determinó el grado de afección según la escala de 8 grados del Colegio Médico UniversitarioInglés, al inicio, a los 45 días y al finalizar el tratamiento. El grupo tratado con EGF presentó mejoría sgnificativa (p<0,01) con respecto al querecibió placebo, encontrándose en el grupo que se utilizó EGF una mejoría general en 23 pacientes (79,3%), destacándose de ellos 15 (51,7%) mucho mejor y8(27,5%) mejor. Ningún paciente empeoró. Esta invención puede emplearse como alternativa terapéutica para el tratamiento del acné crónico.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CU1994136A CU22613A1 (es) | 1994-11-25 | 1994-11-25 | Uso de factor de crecimiento epidérmico para el tratamiento del acne |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR002002A1 true AR002002A1 (es) | 1998-01-07 |
Family
ID=46093359
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP950100314A AR002002A1 (es) | 1994-11-25 | 1995-11-24 | Uso del factor de crecimiento epidermico en la fabricacion de un medicamento en forma de crema hidrofila para el tratamiento del acne. |
Country Status (3)
| Country | Link |
|---|---|
| AR (1) | AR002002A1 (es) |
| CU (1) | CU22613A1 (es) |
| WO (1) | WO1996016669A1 (es) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20170202917A1 (en) * | 2014-05-29 | 2017-07-20 | Daewoong Pharmaceutical Co., Ltd. | Pharmaceutical composition for preventing or treating skin rash |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3380839D1 (en) * | 1983-11-02 | 1989-12-21 | J C R Kabushiki Kaisha Also Kn | Ophthalmic preparations |
| US5023090A (en) * | 1989-08-16 | 1991-06-11 | Levin Robert H | Topical compositions containing LYCD and other topically active medicinal ingredients for the treatment of ACNE |
| CN1083371A (zh) * | 1993-01-03 | 1994-03-09 | 周至惠 | 痤疮、毛囊炎、皮疹特别护理剂 |
-
1994
- 1994-11-25 CU CU1994136A patent/CU22613A1/es unknown
-
1995
- 1995-11-17 WO PCT/NL1995/000392 patent/WO1996016669A1/en not_active Ceased
- 1995-11-24 AR ARP950100314A patent/AR002002A1/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| WO1996016669A1 (en) | 1996-06-06 |
| CU22613A1 (es) | 2000-02-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US4826830A (en) | Topical application of glyciphosphoramide | |
| CA1338779C (en) | Method for treating pain associated with herpes-zoster and post-herpetic neuralgia by topical application of local anesthetics | |
| US7300666B2 (en) | Mixture for transdermal delivery of low and high molecular weight compounds | |
| ES2655876T3 (es) | Extracto de Trigonella foenum-graecum | |
| US20110189307A1 (en) | Methods and compositions for oxygenation of skin to treat skin disorders | |
| EP1684681B1 (en) | A mixture for transdermal delivery of low and high molecular weight compounds | |
| JP7515277B2 (ja) | ロキソプロフェン配合皮膚外用剤 | |
| AR002002A1 (es) | Uso del factor de crecimiento epidermico en la fabricacion de un medicamento en forma de crema hidrofila para el tratamiento del acne. | |
| EP2810641B1 (en) | Topical pharmaceutical and medical device preparations containing combinations of sucralfate, hyaluronic acid, arginine and a natural moisturizing agent | |
| JP6656890B2 (ja) | フィラグリン産生促進剤 | |
| US9585962B1 (en) | Treatment for actinic keratoses | |
| PT1351694E (pt) | Favorecimento da reconstrução celular e/ou da diferenciação celular com açúcar não metabolizável e um absorvente polimérico | |
| Hay et al. | A single application of bifonazole 1% lotion in pityriasis versicolor | |
| US12090133B2 (en) | Topical composition | |
| ES2782826T3 (es) | Preparaciones farmacéuticas tópicas o de dispositivo médico que contienen combinaciones de sucralfato, ácido hialurónico, arginina y un agente humectante natural | |
| MX2025009125A (es) | Fito-composiciones | |
| ES2433249T3 (es) | Extracción de los cambios de piel | |
| ATE91079T1 (de) | Salicylsaeurehaltiges mittel gegen schuppende hauterkrankungen. | |
| HU207446B (en) | Method for producing medicinal preparation of local use | |
| ES2363539T3 (es) | Composición farmacéutica para el tratamiento de la xerostomía. | |
| KR20250083499A (ko) | 통증 및 다른 의학적 병태의 치료를 위한 황화 글리코사미노글리칸 및 이것에서 유래한 단편의 저장에 안정한 제형 | |
| ITRM20130686A1 (it) | Nuova composizione per uso topico | |
| TW202302628A (zh) | 乳鐵蛋白的衍生胜肽及其促進及/或增加油脂生成的用途 | |
| Impey | X rays and high-tension electricity | |
| Swain | Topical 5‐fluorouracil for corns—an effective new treatment |